MapLight reports $450M cash; Phase 2 ZEPHYR & IRIS topline results now expected Q3 2026

MapLight Therapeutics, Inc.

Preliminary cash and equivalents ~$450M as of Dec 31, 2025.
Phase 2 ZEPHYR trial for schizophrenia topline results expected Q3 2026; enrollment ahead of schedule.
Phase 2 IRIS trial for autism spectrum disorder completed enrollment; topline results also Q3 2026.
ZEPHYR is a 300-patient randomized double-blind placebo-controlled trial for acute psychosis.
IRIS trial randomized ~160 adult and adolescent participants with autism spectrum disorder.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.